Case Report: Unremitting COVID-19 Pneumonia, Viral Shedding, and Failure to Develop Anti-SARS-CoV-2 Antibodies for More Than 6 Months in Patient with Mantle Cell Lymphoma Treated with Rituximab

Severe cases of COVID-19 are being reported in patients with comorbidities and drug-induced immunosuppression. The risk seems to depend on the type of immunosuppressive agents used, and it is particularly high with rituximab because of its long-lasting effects. We report a 71-year-old man with COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Berktas, Bahadir M., Koyuncu, Adem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991362/
https://www.ncbi.nlm.nih.gov/pubmed/35213815
http://dx.doi.org/10.4269/ajtmh.21-1010
_version_ 1784683556605263872
author Berktas, Bahadir M.
Koyuncu, Adem
author_facet Berktas, Bahadir M.
Koyuncu, Adem
author_sort Berktas, Bahadir M.
collection PubMed
description Severe cases of COVID-19 are being reported in patients with comorbidities and drug-induced immunosuppression. The risk seems to depend on the type of immunosuppressive agents used, and it is particularly high with rituximab because of its long-lasting effects. We report a 71-year-old man with COVID-19, mantle cell lymphoma, and rituximab-associated immunodeficiency. His COVID-19 clinical course was severe, unremitting, prolonged, and with frequent acute exacerbations requiring hospitalization. Viral shedding and failure to develop anti-severe acute respiratory syndrome coronavirus 2 antibodies continued for at least 6 months.
format Online
Article
Text
id pubmed-8991362
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The American Society of Tropical Medicine and Hygiene
record_format MEDLINE/PubMed
spelling pubmed-89913622022-04-19 Case Report: Unremitting COVID-19 Pneumonia, Viral Shedding, and Failure to Develop Anti-SARS-CoV-2 Antibodies for More Than 6 Months in Patient with Mantle Cell Lymphoma Treated with Rituximab Berktas, Bahadir M. Koyuncu, Adem Am J Trop Med Hyg Case Report Severe cases of COVID-19 are being reported in patients with comorbidities and drug-induced immunosuppression. The risk seems to depend on the type of immunosuppressive agents used, and it is particularly high with rituximab because of its long-lasting effects. We report a 71-year-old man with COVID-19, mantle cell lymphoma, and rituximab-associated immunodeficiency. His COVID-19 clinical course was severe, unremitting, prolonged, and with frequent acute exacerbations requiring hospitalization. Viral shedding and failure to develop anti-severe acute respiratory syndrome coronavirus 2 antibodies continued for at least 6 months. The American Society of Tropical Medicine and Hygiene 2022-04 2022-02-25 /pmc/articles/PMC8991362/ /pubmed/35213815 http://dx.doi.org/10.4269/ajtmh.21-1010 Text en © 2022 by The American Society of Tropical Medicine and Hygiene https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Case Report
Berktas, Bahadir M.
Koyuncu, Adem
Case Report: Unremitting COVID-19 Pneumonia, Viral Shedding, and Failure to Develop Anti-SARS-CoV-2 Antibodies for More Than 6 Months in Patient with Mantle Cell Lymphoma Treated with Rituximab
title Case Report: Unremitting COVID-19 Pneumonia, Viral Shedding, and Failure to Develop Anti-SARS-CoV-2 Antibodies for More Than 6 Months in Patient with Mantle Cell Lymphoma Treated with Rituximab
title_full Case Report: Unremitting COVID-19 Pneumonia, Viral Shedding, and Failure to Develop Anti-SARS-CoV-2 Antibodies for More Than 6 Months in Patient with Mantle Cell Lymphoma Treated with Rituximab
title_fullStr Case Report: Unremitting COVID-19 Pneumonia, Viral Shedding, and Failure to Develop Anti-SARS-CoV-2 Antibodies for More Than 6 Months in Patient with Mantle Cell Lymphoma Treated with Rituximab
title_full_unstemmed Case Report: Unremitting COVID-19 Pneumonia, Viral Shedding, and Failure to Develop Anti-SARS-CoV-2 Antibodies for More Than 6 Months in Patient with Mantle Cell Lymphoma Treated with Rituximab
title_short Case Report: Unremitting COVID-19 Pneumonia, Viral Shedding, and Failure to Develop Anti-SARS-CoV-2 Antibodies for More Than 6 Months in Patient with Mantle Cell Lymphoma Treated with Rituximab
title_sort case report: unremitting covid-19 pneumonia, viral shedding, and failure to develop anti-sars-cov-2 antibodies for more than 6 months in patient with mantle cell lymphoma treated with rituximab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991362/
https://www.ncbi.nlm.nih.gov/pubmed/35213815
http://dx.doi.org/10.4269/ajtmh.21-1010
work_keys_str_mv AT berktasbahadirm casereportunremittingcovid19pneumoniaviralsheddingandfailuretodevelopantisarscov2antibodiesformorethan6monthsinpatientwithmantlecelllymphomatreatedwithrituximab
AT koyuncuadem casereportunremittingcovid19pneumoniaviralsheddingandfailuretodevelopantisarscov2antibodiesformorethan6monthsinpatientwithmantlecelllymphomatreatedwithrituximab

Ejemplares similares